https://investor.cumberlandpharma.com/ 2025-10-15T14:08:39-04:00 daily 1.0 https://investor.cumberlandpharma.com/committee-details/audit-committee 2023-05-12T18:27:30-04:00 0.5 https://investor.cumberlandpharma.com/committee-details/compensation-committee 2023-05-12T19:33:54-04:00 0.5 https://investor.cumberlandpharma.com/committee-details/nominating-committee 2023-06-08T15:40:04-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2016-q3-earnings-call 2016-10-25T12:12:02-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2016-q4-earnings-call 2017-03-01T02:45:11-05:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2017-q1-earnings-call 2017-05-08T12:12:26-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2017-q2-earnings-call 2017-08-01T12:27:04-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2017-q3-earnings-call 2017-10-31T12:10:40-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2017-q4-earnings-call 2018-02-27T14:11:18-05:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2018-q1-earnings-call 2018-05-07T11:06:27-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2018-q2-earnings-call 2018-08-14T16:34:20-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2018-q3-earnings-call 2018-10-03T15:00:43-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2018-q4-earnings-call 2019-02-19T16:24:22-05:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2019-q1-earnings-call 2019-05-07T10:00:35-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2019-q2-earnings-call 2019-08-07T14:09:32-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2019-q3-earnings-call 2019-11-06T09:43:08-05:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-conference-call 2020-01-02T09:40:13-05:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2021-q1-earnings-call 2021-05-04T16:19:49-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2021-q2-earnings-call 2021-08-03T16:10:00-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2021-q3-earnings-call 2021-11-02T16:34:51-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2021-q4-earnings-call 2022-03-01T16:40:51-05:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2022-q1-earnings-call 2022-05-03T16:09:00-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2022-q2-earnings-call 2022-11-01T16:28:47-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2022-q3-earnings-call 2022-11-01T16:28:44-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2022-q4-earnings-call 2023-02-28T16:19:53-05:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2024-q2-earnings-call 2024-07-30T16:10:39-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2024-q3-earnings-call 2024-11-06T11:11:02-05:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2024-q4-earnings-call 2025-07-23T12:05:57-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2025-q1-earnings-call 2025-10-15T14:09:52-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2025-q3-earnings-call 2025-10-28T16:15:53-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2025-q2-earnings-call-0 2025-10-15T14:08:59-04:00 0.5 https://investor.cumberlandpharma.com/events/event-details/cumberland-pharmaceuticals-2025-q4-earnings-call 2026-03-02T14:12:08-05:00 0.5 https://investor.cumberlandpharma.com/investor-relations 2025-10-15T14:08:39-04:00 0.8 https://investor.cumberlandpharma.com/press-releases 2025-10-02T14:39:38-04:00 0.8 https://investor.cumberlandpharma.com/corporate-governance/committee-composition 2017-10-13T02:15:12-04:00 0.8 https://investor.cumberlandpharma.com/corporate-governance/contact-the-board 2025-05-28T04:14:07-04:00 0.8 https://investor.cumberlandpharma.com/financials/financial-information 2025-10-16T15:43:53-04:00 0.8 https://investor.cumberlandpharma.com/financials/sec-filings 2025-05-27T06:35:30-04:00 0.8 https://investor.cumberlandpharma.com/financials/annual-reports 2025-05-28T02:53:01-04:00 0.8 https://investor.cumberlandpharma.com/stock/ownership-profile 2025-05-27T06:34:51-04:00 0.8 https://investor.cumberlandpharma.com/financials/key-ratios 2025-07-21T15:48:07-04:00 0.8 https://investor.cumberlandpharma.com/stock/stock-information 2025-05-27T11:15:28-04:00 0.8 https://investor.cumberlandpharma.com/stock/historic-price-lookup 2025-05-27T11:15:23-04:00 0.8 https://investor.cumberlandpharma.com/investor-faqs 2025-05-27T02:34:26-04:00 0.8 https://investor.cumberlandpharma.com/email-alerts 2017-11-30T04:35:17-05:00 0.8 https://investor.cumberlandpharma.com/printed-materials 2025-05-25T10:37:41-04:00 0.8 https://investor.cumberlandpharma.com/contact-us 2025-07-21T13:02:30-04:00 0.8 https://investor.cumberlandpharma.com/financials/quarterly-results 2025-10-15T13:06:11-04:00 0.8 https://investor.cumberlandpharma.com/events-presentations 2025-10-10T15:01:15-04:00 0.8 https://investor.cumberlandpharma.com/corporate-governance/governance-overview 2025-05-27T06:33:06-04:00 0.8 https://investor.cumberlandpharma.com/vermont-prescribers-information 2025-05-27T04:44:07-04:00 0.8 https://investor.cumberlandpharma.com/policy-managing-conflicts-significant-financial-interests-1 2025-05-27T04:38:03-04:00 0.8 https://investor.cumberlandpharma.com/declaration-compliance-california-1 2025-05-27T04:42:30-04:00 0.8 https://investor.cumberlandpharma.com/phrma-code-compliance-1 2025-05-27T04:41:20-04:00 0.8 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-updated-labeling-acetadoter 2007-08-03T10:57:29-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-new-kristaloser-agreement 2007-08-20T07:58:44-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-acquires-hospital-sales-force 2007-08-20T09:18:51-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-offers-alternative-zelnorm 2007-08-20T09:19:18-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-incfiles-s-1-registration-statement 2007-08-20T09:20:25-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-inc-announces-estimated-price-range 2007-08-20T09:20:52-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-senior-management 2007-11-15T10:31:50-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/kristaloser-offers-prescription-alternative-miralaxr-and-other 2008-07-14T06:28:32-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-launches-acetadoter 2008-07-14T06:34:51-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-names-bill-hix-director-hospital 2008-07-14T06:36:41-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-fda-approval-acetadoter 2008-07-14T06:45:01-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-appoints-senior-executives 2008-07-14T06:46:34-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-launches-us-sales-force-cardinal 2008-07-14T06:48:42-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/bioniche-life-sciences-signs-agreement-cumberland 2008-07-14T06:51:05-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/mylans-bertek-cumberland-pharmaceuticals-announce-promotion 2008-07-14T06:52:21-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-appointments 2008-07-14T07:19:42-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-taps-industry-veteran-key-executive 2008-09-29T13:01:50-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-fda-approval-updated-labeling 2008-12-18T10:29:45-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-appoints-lee-product-director 2009-01-19T11:22:47-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-provides-hospital-service-webcast 2009-05-18T12:00:37-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-fda-approval-caldolor153 2009-06-12T09:22:51-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-pricing-its-initial-public 2009-08-11T04:30:19-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-second-quarter-2009 2009-08-24T12:16:04-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-second-quarter-2009-financial 2009-08-27T03:31:06-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-present-ubs-global-life-sciences 2009-08-31T12:31:06-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-launches-caldolorr-united-states 2009-09-09T03:31:09-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-inc-cpix-chief-executive-officer-aj 2009-09-18T11:48:56-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-presentation-caldolor-data 2009-10-05T03:31:11-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/newly-published-clinical-data-shows-caldolorr-ibuprofen 2009-10-19T07:46:06-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-third-quarter-2009-financial 2009-10-27T06:01:09-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-and-phebra-pty-ltd-sign-exclusive 2009-10-29T08:28:04-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-present-lazard-healthcare-conference 2009-11-02T04:49:04-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-58-increase-net-revenue-third 2009-11-10T02:34:09-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-ibuprofen-injection-demonstrates-significant-fever 2009-11-23T04:04:35-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/newly-published-acetadoter-data-shows-product-can-provide 2009-12-01T07:37:05-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/new-caldolorr-ibuprofen-injection-data-be-presented-44th 2009-12-03T06:31:03-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-licenses-caldolorr-ibuprofen 2009-12-09T04:04:42-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/kristaloser-preferred-patients-chronic-constipation-compared 2009-12-15T08:28:04-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-data-be-presented-during-critical-care-conference 2010-01-05T09:52:04-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-donates-caldolorr-haitian-relief 2010-01-20T06:34:05-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-year-end-2009-financial 2010-02-24T10:16:03-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/new-data-caldolorr-study-burn-patients-be-presented-42nd-annual 2010-03-02T07:22:14-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/key-caldolorr-orthopedic-data-be-presented-american-academy 2010-03-04T08:04:25-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-24-increase-net-revenue-full 2010-03-10T03:40:08-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/acetadoter-supplemental-new-drug-application-acute-liver-failure 2010-03-30T02:34:08-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ibuprofen-compares-favorably-acetaminophen-newly-published-meta 2010-04-13T06:01:52-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-adds-three-board-new-elections-annual 2010-04-20T09:31:05-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/kristaloser-clinical-data-be-presented-digestive-disease-weekr 2010-04-26T07:43:03-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-partners-canada-alveda 2010-04-28T06:31:29-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-first-quarter-2010-financial 2010-05-03T06:04:11-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/acetadoter-approved-australia-treatment-acetaminophen-poisoning 2010-05-11T08:19:04-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-first-quarter-2010-earnings 2010-05-13T12:04:12-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-present-jefferies-global-life 2010-05-20T12:01:06-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-present-wells-fargo-healthcare 2010-06-03T12:07:18-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-ibuprofen-injection-shown-significantly-reduce-fever 2010-07-12T06:31:10-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-second-quarter-2010 2010-07-28T08:31:07-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-present-bmo-capital-markets-10th 2010-07-29T12:54:14-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-present-bank-america-merrill-lynch 2010-08-02T09:16:06-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-second-quarter-2010-financial 2010-08-16T12:01:28-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-extension-fda-review 2010-08-20T12:07:06-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/pre-and-post-operative-use-caldolorr-ibuprofen-injection 2010-08-30T09:16:06-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-share-purchases-senior 2010-08-31T08:41:07-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-responds-fda-regarding-acetadote 2010-08-31T08:41:57-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-share-repurchase-program 2010-08-31T08:43:23-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-present-stifel-nicolaus-2010 2010-09-08T13:26:42-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-present-ubs-global-life-sciences-0 2010-09-13T07:16:04-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-ibuprofen-injection-gaining-approval-formulary-us 2010-09-23T09:31:06-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/newly-published-caldolorr-clinical-data-demonstrates-77 2010-10-07T11:19:14-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-and-phebra-pty-ltd-announce-launch 2010-10-14T09:46:07-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-third-quarter-2010-financial 2010-10-28T09:34:08-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-third-quarter-2010-financial 2010-11-11T11:06:42-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/newly-published-data-shows-kristalose-preferred-77-more-patients 2010-12-01T10:42:10-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/fda-issues-complete-response-letter-regarding-acetadoter 2010-12-22T01:33:13-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-voluntary-recall-acetadoter 2010-12-30T11:06:11-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-joey-jacobs-has-joined-its 2011-01-06T01:48:12-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-receives-fda-approval-new-formulation 2011-01-13T12:09:11-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/newly-published-data-demonstrates-caldolorr-significantly 2011-01-27T01:48:12-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-rapid-infusion-shown-be-safe-and-well-tolerated-newly 2011-02-15T11:09:12-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-2010-financial-results-march 2011-02-17T01:48:10-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-appoints-tan-cheow-choon-director 2011-02-24T12:51:10-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/anesthesiologists-use-caldolorr-provide-preemptive-pain-control 2011-03-02T11:48:14-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-fourth-quarter-and-full-year 2011-03-10T10:50:56-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/new-acetadoter-formulation-now-available-us 2011-03-22T13:15:08-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-appoints-rick-s-greene-vice-president 2011-04-04T13:33:08-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-new-product-addition 2011-04-19T02:48:08-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-first-quarter-2011-financial 2011-04-22T02:48:08-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-first-quarter-2011-financial 2011-05-04T12:05:02-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-present-2011-ubs-global-specialty 2011-05-11T12:07:05-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-clinical-study-hospitalized-burn-patients-published 2011-05-16T02:48:07-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-present-2011-wells-fargo-securities 2011-06-07T12:03:12-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-second-quarter-2011 2011-07-14T12:57:09-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-inks-new-bank-financing-deal-bank 2011-08-04T09:06:07-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-second-quarter-2011-financial 2011-08-04T12:03:59-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-present-stifel-nicolaus-2011 2011-08-25T11:12:08-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-present-ubs-global-life-sciences-1 2011-08-31T08:42:10-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-appoints-rick-s-greene-chief 2011-10-12T12:54:09-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-third-quarter-2011-financial 2011-10-13T12:06:24-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-third-quarter-2011-financial 2011-11-04T08:25:54-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-ranks-one-fastest-growing-companies-0 2011-11-14T10:57:50-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-2011-year-end-financial 2012-02-08T07:09:08-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-receives-acetadoter-patent-notice-allowance 2012-02-08T11:24:08-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-signs-exclusive-licensing-agreement 2012-02-28T11:06:55-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-2011-annual-financial-results 2012-02-29T11:12:33-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-present-needham-life-sciences 2012-03-27T12:33:15-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-first-quarter-2012-financial 2012-04-12T12:06:18-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-first-quarter-2012-financial 2012-05-03T12:10:19-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-present-2012-wells-fargo-securities 2012-06-13T08:51:06-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-second-quarter-2012 2012-07-12T12:06:27-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-second-quarter-2012-financial 2012-08-02T12:10:22-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-present-ubs-global-life-sciences-2 2012-09-06T12:33:21-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-reduces-narcotic-doses-pediatric-pain-patients 2012-09-19T07:10:41-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cet-life-sciences-center-tenants-receive-federal-small-business 2012-10-11T13:39:10-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-third-quarter-2012-financial 2012-10-18T12:13:33-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-third-quarter-2012-financial 2012-11-01T12:04:31-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-receives-second-acetadoter-patent-notice-allowance 2012-11-07T04:04:11-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-emerging-technologies-expands-life-sciences-center 2013-01-02T08:03:37-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-and-pt-soho-industri-pharmasi-enter 2013-01-29T04:36:11-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-2012-year-end-financial 2013-02-14T11:33:30-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-reduces-pain-and-fever-adult-patients 2013-02-19T02:04:47-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-licenses-caldolorr-ibuprofen-0 2013-02-21T02:04:17-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-2012-annual-financial-results 2013-02-28T11:03:50-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-first-quarter-2013-financial 2013-04-25T12:11:22-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-first-quarter-financial 2013-05-02T12:12:43-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-present-ubs-global-healthcare 2013-05-15T11:00:24-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-fda-approval-updated 2013-06-13T09:37:22-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-second-quarter-2013 2013-07-29T12:10:54-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-second-quarter-financial 2013-08-06T12:11:28-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-studies-be-presented-annual-meeting-american-society 2013-10-10T12:07:50-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-and-pernix-therapeutics-enter 2013-10-28T04:05:44-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-third-quarter-2013-financial 2013-10-29T12:12:00-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-third-quarter-financial 2013-11-05T11:11:53-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-2013-year-end-financial 2014-02-27T08:30:16-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-acquires-vaprisolr-astellas-pharma-us 2014-03-03T03:09:33-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-2013-fourth-quarter-and 2014-03-04T11:07:27-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-pediatric-pain-study-results-be-presented-pediatric 2014-03-07T13:33:06-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-first-quarter-2014-financial 2014-04-29T13:01:00-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-and-gloria-pharmaceuticals-announce 2014-05-06T03:05:34-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-launches-vaprisolr-promotion 2014-05-07T03:05:12-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-first-quarter-2014-financial 2014-05-13T12:07:31-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-second-quarter-2014 2014-07-22T12:07:06-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-second-quarter-2014-financial 2014-08-05T12:14:29-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-provides-favorable-inflammatory-response-results 2014-10-10T11:12:08-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-safely-treats-fever-hospitalized-children 2014-10-14T12:06:57-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-third-quarter-2014-financial 2014-10-21T12:10:53-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-third-quarter-2014-financial 2014-11-04T11:10:19-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/phase-iv-studies-published-supporting-safety-shortened-infusion 2015-02-02T03:31:49-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-pipeline-expansion 2015-02-11T05:00:29-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-fourth-quarter-and-annual 2015-02-24T03:08:21-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-return-growth-and 2015-03-03T11:07:23-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-clinical-and-regulatory 2015-03-03T12:30:37-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-first-quarter-2015-financial 2015-04-30T12:20:34-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-first-quarter-2015-financial 2025-08-13T04:00:33-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-second-quarter-2015 2025-08-13T03:58:08-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-second-quarter-year-date-2015 2025-08-13T03:57:10-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-and-clinigen-group-announce-strategic 2025-08-13T03:56:23-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/new-caldolor-integrated-safety-analysis-published-supporting 2025-08-13T03:41:30-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-third-quarter-2015-financial 2025-08-13T03:36:07-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-third-quarter-year-date-2015 2025-08-13T03:34:59-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-and-piramal-enterprises-announce-co 2025-08-13T03:33:53-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-favorable-acetadoter-patent 2025-08-13T03:32:53-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-launched-australia-treatment-pain-and-fever 2025-08-13T03:31:51-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolor-approved-use-pediatric-patients 2015-11-23T14:26:50-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/piramal-critical-care-and-cumberland-pharmaceuticals-announce 2025-08-13T03:31:07-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/vaprisol-dose-comparison-published-supporting-its-efficacy 2025-08-13T03:30:26-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-fourth-quarter-and-annual-0 2025-08-13T03:29:14-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-fourth-quarter-and-full-0 2025-08-13T03:28:21-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-launched-treatment-pain-and-fever-children 2025-08-13T03:27:28-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-new-program-develop 2025-08-13T03:26:48-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-first-quarter-2016-financial 2025-08-13T03:26:03-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-and-clinigen-group-enter-exclusive-us 2025-08-13T03:25:32-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-first-quarter-2016-financial 2016-05-10T12:06:05-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-caroline-young-join-its 2025-08-13T03:24:41-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-participate-avondale-partners-4th 2025-08-13T03:21:26-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-second-quarter-2016 2025-08-13T03:20:07-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-second-quarter-2016-financial 2025-08-13T03:19:21-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-begins-us-shipments-ethyolr 2025-08-13T03:17:53-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-new-program-develop-0 2025-08-13T03:17:13-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-launches-promotion-ethyolr-united 2025-08-13T03:07:29-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-third-quarter-2016-financial 2025-08-13T02:57:33-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-third-quarter-year-date-2016 2025-08-13T02:56:45-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-acquires-us-rights-nordic-groups 2025-08-13T02:55:57-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-emerging-technologies-announces-new-small-business 2016-11-30T11:49:48-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-emerging-technologies-appoints-new-senior-executive 2017-01-04T11:17:13-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-and-clinigen-enter-exclusive-us 2025-08-13T02:54:44-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-kenneth-j-krogulski-join 2025-08-13T02:47:49-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/us-court-appeals-affirms-cumberland-pharmaceuticals-victory 2025-08-13T02:43:22-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-pediatric-fever-study-published-supporting-its 2017-02-07T03:16:00-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-fourth-quarter-and-annual-1 2025-08-13T02:41:01-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-fourth-quarter-and-full-1 2025-08-13T02:39:23-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-demonstrates-significant-post-surgical-pain-reduction 2025-08-13T02:38:17-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/new-vaprisol-study-supports-reduced-dose-patients-severe-liver 2017-04-03T04:08:46-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/new-kristaloser-growth-driver-established-through-co-promotion 2025-08-13T02:36:35-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-first-quarter-2017-financial 2025-08-13T02:35:21-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-revenue-growth-25-first 2025-08-13T02:34:30-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/clinigen-and-cumberland-pharmaceuticals-obtain-fda-approval 2017-07-10T04:09:28-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-begin-us-shipments-dexrazoxane 2025-08-13T02:33:32-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-second-quarter-2017 2025-08-13T02:32:22-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceutical-reports-double-digit-revenue-growth 2025-08-13T02:31:11-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-launches-promotion-totectr-us 2025-08-13T02:29:20-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-third-quarter-2017-financial 2025-08-13T02:20:59-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceutical-reports-27-revenue-growth-third 2025-08-13T02:17:05-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/newly-published-data-demonstrates-amifostine-reduces-gastro 2025-08-13T02:13:54-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-fourth-quarter-and-annual-2 2025-08-13T02:12:19-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-25-revenue-growth-full-year 2025-08-13T02:10:45-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/newly-published-data-demonstrates-85-eradication-ulcer-causing 2025-08-13T02:09:03-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-expands-oncology-support 2025-08-13T02:07:53-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-first-quarter-2018-financial 2025-08-13T02:05:33-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-first-quarter-2018-financial 2025-08-13T02:00:07-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/lsu-health-new-orleans-and-cumberland-emerging-technologies 2025-09-16T06:32:12-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-appoints-new-senior-executive 2018-06-04T13:12:08-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-emerging-technologies-announces-board-appointments 2025-09-16T06:31:06-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-second-quarter-2018 2025-08-13T01:44:57-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-appoints-new-senior-executive-0 2025-08-13T01:44:14-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-second-quarter-2018-financial 2025-08-13T01:42:46-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-senior-music-industry 2018-09-24T10:02:17-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/newly-published-data-demonstrates-amifostine-delayed-onset-acute 2018-09-27T09:03:23-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolor-administered-prior-surgery-provides-more-effective-pain 2018-10-24T18:40:23-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/new-study-demonstrates-superiority-caldolorr-over-iv 2025-09-16T06:30:27-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-acquire-vibativr 2025-08-13T01:40:39-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-third-quarter-2018-financial 2025-08-13T01:39:11-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-third-quarter-2018-financial 2025-08-13T01:38:09-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-fourth-quarter-and-annual-3 2025-08-13T01:36:36-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-fourth-quarter-revenue-growth 2025-08-13T01:35:03-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-strategic-review 2025-08-13T01:33:15-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-first-quarter-2019-financial 2025-08-13T01:32:33-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-38-revenue-growth-first 2025-08-13T01:25:58-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-signs-exclusive-licensing-agreement-0 2025-08-13T01:25:10-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-emerging-technologies-welcomes-launch-tennessees 2019-06-10T12:11:38-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-second-quarter-2019 2025-08-13T01:24:26-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-14-revenue-growth-second 2025-08-13T01:14:06-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-fda-orphan-drug-grant-award 2025-08-13T01:13:04-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-emerging-technologies-appoints-new-senior-executive-0 2025-09-16T06:29:43-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/new-study-reveals-superiority-vibativr-over-vancomycin-select 2025-08-13T01:12:09-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-third-quarter-2019-financial 2025-08-13T01:09:45-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-22-revenue-growth-third 2025-08-13T01:08:00-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/new-study-reveals-real-world-usage-vibativr-variety-infections 2025-08-13T01:03:47-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-receives-fda-approval-reditrextm 2025-08-13T01:02:01-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-hold-update-call-discuss-recent-major 2025-08-13T01:00:50-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-national-launch-new 2025-08-13T01:00:02-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-fourth-quarter-and-annual-4 2025-08-13T00:58:39-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reschedules-fourth-quarter-and-annual 2025-08-13T00:57:50-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-demonstrates-favorable-safety-profile-newborns 2025-08-13T00:56:53-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-17-revenue-growth-full-year 2020-03-18T16:05:49-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-initiative-expand 2025-08-13T00:43:07-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-initiative-expand-0 2025-08-13T00:34:17-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/help-prepare-covid-19-patient-surge-cumberland-pharmaceuticals 2025-08-13T00:33:16-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-releases-inaugural-report-its 2025-08-13T00:32:01-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/vibativr-sustained-potency-confirmed-two-surveillance-studies 2025-08-13T00:31:21-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-first-quarter-2020-financial 2025-08-13T00:30:39-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-first-quarter-2020-financial 2025-08-13T00:29:41-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/new-publication-reveals-real-world-usage-vibativr-patients 2025-08-13T00:11:01-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/vibativr-bacteremia-study-data-now-available 2020-06-15T09:30:27-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cet-life-sciences-center-welcomes-advansta-new-tenant 2020-07-01T09:13:35-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-demonstrates-significant-reduction-opioid-use 2025-08-13T00:09:56-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-second-quarter-2020 2025-08-13T00:06:56-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-second-quarter-2020-financial 2025-08-13T00:04:47-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/newly-published-literature-supports-use-caldolorr-postoperative 2025-08-13T00:03:54-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cet-life-sciences-center-welcomes-yaya-scientific-new-tenant 2020-10-05T08:37:33-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-third-quarter-2020-financial 2025-08-13T00:02:37-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-third-quarter-2020-financial 2025-08-13T00:00:48-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/introducing-reditrexr-new-methotrexate-delivery-system 2025-08-12T23:58:44-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-fourth-quarter-and-annual-5 2025-08-12T23:56:22-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-9-revenue-growth-2020 2025-08-12T23:54:32-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-emerging-technologies-names-van-tucker-board 2021-03-15T12:03:20-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-first-quarter-2021-financial 2025-08-12T23:53:03-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-first-quarter-2021-financial 2025-08-12T23:51:30-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-names-john-hamm-new-chief-financial 2021-05-19T15:30:57-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/vibativr-effectively-helps-treat-secondary-bacterial-infections 2025-08-12T23:50:16-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-25m-patient-doses-delivered 2025-08-12T23:46:07-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-second-quarter-2021 2025-08-12T23:40:41-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-second-quarter-2021-financial 2025-08-12T23:38:59-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-launches-reditrexr-product-line 2025-08-12T23:37:40-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-third-quarter-2021-financial 2025-08-12T23:36:51-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-third-quarter-2021-financial 2025-08-12T23:35:28-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-moving-corporate-headquarters 2021-11-19T12:39:26-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-now-fda-approved-pre-operative-administration 2025-08-12T23:32:38-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ceo-message-1 2023-05-12T19:03:37-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-acquires-sancusor-kyowa-kirin-north 2025-09-16T06:28:18-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-annual-2021-financial 2025-09-16T06:27:44-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-2021-financial-results 2025-09-16T06:27:14-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/company-update-march-2022 2022-03-14T13:53:05-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/fda-approved-antibiotic-life-saving-potential-launches-puerto 2025-09-16T06:26:20-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/tabuk-and-cumberland-partner-bring-innovative-antibiotic-life 2025-09-16T06:25:34-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-first-quarter-2022-financial 2025-09-16T06:25:03-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-key-co-promotion-agreement 2025-08-12T23:14:05-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ceo-message-2 2022-05-10T16:09:06-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-6-revenue-growth 2025-08-12T23:12:55-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-appoints-martin-brown-jr-its-board 2025-09-16T06:24:07-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-second-quarter-2022 2025-09-16T06:22:15-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-24m-patient-doses-delivered 2025-09-16T06:21:44-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-14-revenue-growth 2025-08-12T23:08:24-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-moves-new-headquarters-broadwest 2025-09-16T06:21:04-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-third-quarter-2022-financial 2025-09-16T06:20:24-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-41-revenue-growth 2025-08-12T23:05:20-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-annual-2022-financial 2025-09-16T06:18:25-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-17-revenue-growth-full-year-0 2025-09-16T06:17:44-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-first-quarter-2023-financial 2025-09-16T06:14:52-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-first-quarter-2023-financial 2025-08-21T13:37:58-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ceo-message-8 2023-05-15T09:00:02-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ceo-message-3 2023-05-12T19:07:23-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ceo-message-4 2023-05-12T19:07:50-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ceo-message-5 2023-05-12T19:07:57-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ceo-message-6 2023-05-12T19:11:28-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ceo-message-7 2023-05-12T19:11:32-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-now-fda-approved-treatment-fever-pain-infants 2025-09-16T06:14:15-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-fda-clearance-ind-new 2025-09-16T06:12:49-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/new-publication-supports-use-caldolorr-newborn-pediatric 2025-09-16T06:12:04-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-second-quarter-2023 2025-09-16T06:11:25-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-revenue-and-earnings-growth 2025-08-21T13:37:31-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ceo-message-9 2023-08-14T09:41:07-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/new-vibativr-pediatric-publication-highlights-its-safety 2025-09-16T06:03:52-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-third-quarter-2023-financial 2025-09-16T06:02:47-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-third-quarter-2023-financial 2025-08-21T13:37:21-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ceo-message-10 2023-11-13T11:29:01-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-annual-2023-financial-0 2025-09-16T06:01:21-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ceo-message-11 2024-03-12T10:05:22-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-annual-2023-financial-results 2025-08-21T13:37:12-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/new-report-supports-use-caldolorr-standard-care-across-patient 2025-09-16T06:00:49-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-first-quarter-2024-financial 2025-09-16T05:59:53-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-first-quarter-2024-financial 2025-08-21T13:35:10-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ceo-message-12 2024-05-14T10:20:21-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-second-quarter-2024 2025-09-16T05:59:09-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-16-sequential-revenue-growth 2025-08-21T13:34:16-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ceo-message-13 2024-08-13T14:25:25-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-third-quarter-2024-financial 2025-09-16T05:58:00-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/new-study-compares-caldolorr-ibuprofen-injection-ketorolac 2025-08-21T13:18:29-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-receives-fda-orphan-drug-and-rare 2025-09-16T05:53:43-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-third-quarter-2024-financial 2025-08-13T12:23:04-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ceo-message-14 2024-11-14T08:30:00-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/fda-approves-acetadoter-snda-0 2025-09-16T05:50:21-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-breakthrough-results-phase 2025-08-13T12:22:37-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/vibativr-receives-marketing-approval-china 2025-09-16T05:48:31-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-annual-2024-financial 2025-09-16T05:46:58-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-116-fourth-quarter-2024 2025-08-13T12:22:13-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ceo-message-15 2025-03-11T14:35:08-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/fight-dmd-trial-results-selected-late-breaking-presentation-mda 2025-08-13T12:21:58-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-q1-2025-financial-results 2025-09-16T05:45:40-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-38-revenue-growth-q1-2025 2025-08-13T12:21:41-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-partners-qureight-advance-innovative 2025-09-16T05:44:24-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/new-study-finds-caldolorr-safe-and-effective-opioid-sparing-pain 2025-09-16T05:43:26-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/ceo-message-16 2025-06-04T15:58:17-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-shares-phase-2-fight-dmd-trial 2025-08-13T12:21:05-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-q2-2025-financial-results 2025-09-16T05:42:24-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-receives-vizient-contract-new 2025-09-16T05:41:41-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-23-revenue-growth-year-date 2025-08-18T11:59:15-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/tabuk-launches-vibativr-fda-approved-antibiotic-life-saving 2025-10-03T17:58:59-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announces-product-approval-mexico 2025-10-03T18:01:04-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-vibativr-added-national-group 2025-10-30T17:36:18-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-phamaceuticals-announces-addition-established-fda 2025-10-30T17:35:43-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-q3-2025-financial-results 2025-10-30T17:34:56-04:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-12-year-date-revenue-growth 2025-11-04T17:12:06-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/caldolorr-ibuprofen-injection-cms-issued-j-code-now-associated 2025-12-08T09:05:17-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-receives-fda-fast-track-designation 2026-02-04T09:07:07-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-announce-2025-annual-financial 2026-02-24T16:31:44-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-launches-us-promotion-taliciar 2026-02-25T11:16:07-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-reports-31-fourth-quarter-2025 2026-03-03T17:16:10-05:00 0.5 https://investor.cumberlandpharma.com/news-releases/news-release-details/cumberland-pharmaceuticals-launches-new-sancusor-website 2026-03-17T11:53:51-04:00 0.5 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-20-000118 2025-08-12T01:13:46-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-20-000294 2025-08-12T01:13:49-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/sc-13g/0001628280-20-001202 2025-08-12T01:13:53-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/sc-13ga/0001258897-20-000940 2025-08-12T01:13:57-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/sc-13ga/0000935836-20-000112 2025-08-12T01:14:01-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/sc-13ga/0000936753-20-000054 2025-08-12T01:14:04-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-20-003774 2025-08-12T01:14:09-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-k/0001628280-20-003880 2025-08-12T01:14:20-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/def-14a/0001628280-20-003882 2025-08-12T01:14:15-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-20-024873 2025-08-12T01:15:09-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-20-024872 2025-08-12T01:14:44-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-20-024878 2025-08-12T01:14:25-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-20-024876 2025-08-12T01:14:53-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-20-024880 2025-08-12T01:14:30-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-20-024884 2025-08-12T01:14:59-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-20-024896 2025-08-12T01:14:35-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-20-024892 2025-08-12T01:15:03-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-20-024889 2025-08-12T01:14:41-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-20-024900 2025-08-12T01:15:11-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-20-024903 2025-08-12T01:14:49-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-20-005204 2025-08-12T01:15:16-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-20-006158 2025-08-12T01:15:21-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-20-007252 2025-08-12T01:15:26-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-20-007253 2025-08-12T01:15:31-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-20-008136 2025-08-12T01:15:35-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-20-008312 2025-08-12T01:15:40-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-20-008691 2025-08-12T01:15:44-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-20-036360 2025-08-12T01:15:49-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-qa/0001628280-20-010607 2025-08-12T01:16:05-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-20-012444 2025-08-12T01:16:10-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-20-012738 2025-08-12T01:16:15-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-20-048659 2025-08-12T01:16:21-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-20-014431 2025-08-12T01:05:55-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-20-016214 2025-08-12T01:06:08-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-20-016446 2025-08-12T01:06:12-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/upload/0000000000-20-009927 2025-08-12T01:06:02-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/corresp/0001628280-20-014541 2025-08-12T01:05:58-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-20-017370 2025-08-12T01:06:33-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/s-3/0001628280-20-017414 2025-08-12T01:06:39-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/effect/9999999995-21-000090 2025-08-12T01:06:48-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/5/0001209191-21-008216 2025-08-12T01:06:55-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/5/0001209191-21-008220 2025-08-12T01:07:32-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/5/0001209191-21-008218 2025-08-12T01:07:04-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/5/0001209191-21-008222 2025-08-12T01:07:42-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/5/0001209191-21-008224 2025-08-12T01:07:11-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/5/0001209191-21-008227 2025-08-12T01:08:16-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/5/0001209191-21-008229 2025-08-12T01:07:23-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/5/0001209191-21-008231 2025-08-12T01:06:52-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/5/0001209191-21-008244 2025-08-12T01:07:29-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/5/0001209191-21-008265 2025-08-12T01:07:00-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/5/0001209191-21-008269 2025-08-12T01:07:38-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/5/0001209191-21-008272 2025-08-12T01:07:09-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/5/0001209191-21-008274 2025-08-12T01:08:05-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/5/0001209191-21-008276 2025-08-12T01:07:16-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/5/0001209191-21-008280 2025-08-12T01:08:21-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/corresp/0001628280-21-000216 2025-08-12T01:06:45-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/sc-13ga/0000936753-21-000038 2025-08-12T01:08:25-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/sc-13ga/0000354204-21-000346 2025-08-12T01:08:35-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/sc-13ga/0000935836-21-000120 2025-08-12T01:08:30-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/sc-13g/0001628280-21-002133 2025-08-12T01:08:40-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-21-004286 2025-08-12T01:08:44-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-k/0001628280-21-004654 2025-08-12T01:08:50-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/def-14a/0001628280-21-004751 2025-08-12T01:08:53-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-21-008486 2025-08-12T01:08:57-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-21-009844 2025-08-12T01:09:01-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-21-010387 2025-08-12T01:09:07-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-21-010388 2025-08-12T01:09:12-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-038980 2025-08-12T01:09:16-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-039917 2025-08-12T01:10:08-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-039925 2025-08-12T01:09:39-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-039926 2025-08-12T01:10:18-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-039928 2025-08-12T01:09:47-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-039931 2025-08-12T01:09:22-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-039933 2025-08-12T01:09:51-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-039932 2025-08-12T01:09:29-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-039936 2025-08-12T01:10:01-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-039934 2025-08-12T01:09:36-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-039938 2025-08-12T01:10:13-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-21-012190 2025-08-12T01:10:23-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/sc-13ga/0000936753-21-000064 2025-08-12T00:57:23-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/3/0001209191-21-046206 2025-08-12T00:57:16-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-046210 2025-08-12T00:57:26-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-046212 2025-08-12T00:57:18-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-21-016443 2025-08-12T00:57:31-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-21-017022 2025-08-12T00:57:35-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-051433 2025-08-12T00:57:46-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-051438 2025-08-12T00:57:39-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-051441 2025-08-12T00:57:51-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-051443 2025-08-12T00:57:44-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/corresp/0001628280-20-013756 2025-08-12T01:05:49-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/corresp/0001628280-20-010552 2025-08-12T01:16:00-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/upload/0000000000-20-006126 2025-08-12T01:15:56-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/upload/0000000000-20-008946 2025-08-12T01:05:51-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/upload/0000000000-20-012051 2025-08-12T01:06:42-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-055478 2025-08-12T00:58:44-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-055480 2025-08-12T00:58:19-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-055483 2025-08-12T00:57:55-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-055485 2025-08-12T00:58:28-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-055488 2025-08-12T00:58:04-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-055490 2025-08-12T00:58:34-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-055492 2025-08-12T00:58:09-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-055494 2025-08-12T00:58:38-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-055496 2025-08-12T00:58:14-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-055500 2025-08-12T00:58:48-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-055504 2025-08-12T00:58:24-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-055507 2025-08-12T00:57:59-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-058506 2025-08-12T00:59:09-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-058512 2025-08-12T00:58:55-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-058517 2025-08-12T00:59:17-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-058521 2025-08-12T00:59:00-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-058527 2025-08-12T00:59:21-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-058530 2025-08-12T00:59:05-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-21-021025 2025-08-12T00:59:25-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-063217 2025-08-12T00:59:30-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-063219 2025-08-12T00:59:45-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-063222 2025-08-12T00:59:34-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-063225 2025-08-12T00:59:49-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-063228 2025-08-12T00:59:40-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-063235 2025-08-12T00:59:55-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-21-022599 2025-08-12T01:00:00-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-21-023213 2025-08-12T01:00:08-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-21-023902 2025-08-12T01:00:22-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-21-024264 2025-08-12T01:00:26-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-067878 2025-08-12T01:01:02-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-067883 2025-08-12T01:00:40-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-067892 2025-08-12T01:01:06-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-067893 2025-08-12T01:00:53-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-067888 2025-08-12T01:01:12-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-067899 2025-08-12T01:00:57-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-21-067905 2025-08-12T01:00:34-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/424b5/0001628280-21-025611 2025-08-12T01:01:32-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-21-025612 2025-08-12T01:03:06-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-22-000008 2025-08-12T01:01:40-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-22-000440 2025-08-12T01:01:44-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-002447 2025-08-12T00:51:22-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-002451 2025-08-12T00:51:15-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-002457 2025-08-12T00:51:25-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-002462 2025-08-12T00:51:18-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-002468 2025-08-12T00:51:29-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/sc-13ga/0000354204-22-001705 2025-08-12T00:51:33-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/sc-13g/0001628280-22-002546 2025-08-12T00:51:38-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-22-005405 2025-08-12T00:51:41-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-k/0001628280-22-005942 2025-08-12T00:51:45-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/def-14a/0001628280-22-006406 2025-08-12T00:51:51-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-22-006568 2025-08-12T00:51:55-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-ka/0001628280-22-006570 2025-08-12T00:52:01-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-22-006915 2025-08-12T00:52:07-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-22-010078 2025-08-12T00:52:11-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-026135 2025-08-12T00:52:37-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-026138 2025-08-12T00:52:20-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-026140 2025-08-12T00:52:43-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-026142 2025-08-12T00:52:24-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-026144 2025-08-12T00:52:48-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-026146 2025-08-12T00:52:28-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-026148 2025-08-12T00:52:52-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-026150 2025-08-12T00:52:32-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-026152 2025-08-12T00:52:18-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-026154 2025-08-12T00:52:40-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-22-012039 2025-08-12T00:52:57-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-027643 2025-08-12T00:53:08-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-027646 2025-08-12T00:53:01-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-027649 2025-08-12T00:53:13-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-027651 2025-08-12T00:53:05-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-22-013656 2025-08-12T00:53:19-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-22-014372 2025-08-12T00:53:23-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-22-016201 2025-08-12T00:53:29-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-035983 2025-08-12T00:53:42-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-035994 2025-08-12T00:53:33-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-036001 2025-08-12T00:53:46-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-036008 2025-08-12T00:53:39-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-040094 2025-08-12T00:54:13-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-040099 2025-08-12T00:54:03-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-040104 2025-08-12T00:53:50-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-040108 2025-08-12T00:54:08-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-040113 2025-08-12T00:53:56-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-22-019114 2025-08-12T00:54:18-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/3/0001209191-22-043130 2025-08-12T00:54:22-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-22-021989 2025-08-12T00:54:27-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-22-022735 2025-08-12T00:54:32-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-046894 2025-08-12T00:54:37-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-046896 2025-08-12T00:54:45-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-046898 2025-08-12T00:54:41-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-046900 2025-08-12T00:54:50-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-051665 2025-08-12T00:54:55-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-051667 2025-08-12T01:18:36-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-051669 2025-08-12T00:44:33-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-051671 2025-08-12T00:44:24-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-22-028987 2025-08-12T00:44:37-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-22-029906 2025-08-12T00:44:44-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-057939 2025-08-12T00:44:47-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-057942 2025-08-12T00:44:56-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-057945 2025-08-12T00:44:53-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-057947 2025-08-12T00:45:00-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-22-031743 2025-08-12T00:45:05-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-062641 2025-08-12T00:45:43-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-062643 2025-08-12T00:45:25-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-062645 2025-08-12T00:45:09-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-062647 2025-08-12T00:45:29-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-062649 2025-08-12T00:45:13-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-062651 2025-08-12T00:45:34-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-062657 2025-08-12T00:45:17-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-22-062654 2025-08-12T00:45:38-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-001129 2025-08-12T00:45:47-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/sc-13g/0001628280-23-003182 2025-08-12T00:45:53-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-006782 2025-08-12T00:45:56-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-k/0001628280-23-007727 2025-08-12T00:46:02-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-007952 2025-08-12T00:46:10-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/def-14a/0001628280-23-007954 2025-08-12T00:46:05-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/defa14a/0001628280-23-007956 2025-08-12T00:46:14-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/3/0001209191-23-020071 2025-08-12T00:46:18-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/3/0001209191-23-020080 2025-08-12T00:46:24-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-23-020349 2025-08-12T00:46:34-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-23-020346 2025-08-12T00:46:28-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-23-020351 2025-08-12T00:46:38-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/ars/0001628280-23-008932 2025-08-12T00:46:44-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-23-021266 2025-08-12T00:47:24-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-23-021262 2025-08-12T00:47:03-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-23-021276 2025-08-12T00:47:34-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-23-021278 2025-08-12T00:47:08-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-23-021280 2025-08-12T00:46:47-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-23-021282 2025-08-12T00:47:14-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-23-021284 2025-08-12T00:46:53-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-23-021288 2025-08-12T00:47:18-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-23-021286 2025-08-12T00:46:57-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001209191-23-021290 2025-08-12T00:47:30-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-010469 2025-08-12T00:47:39-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-011672 2025-08-12T00:47:44-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-014265 2025-08-12T00:47:49-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-016892 2025-08-12T00:47:55-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-23-017951 2025-08-12T00:48:00-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/s-8/0001628280-23-018465 2025-08-12T00:48:05-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-018467 2025-08-12T00:48:14-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-019604 2025-08-12T00:48:21-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-020697 2025-08-12T00:48:26-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-021318 2025-08-12T00:20:11-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-022935 2025-08-12T00:20:15-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-024065 2025-08-12T00:20:21-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-028289 2025-08-12T00:20:26-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-23-029112 2025-08-12T00:20:30-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-031458 2025-08-12T00:20:34-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-012221 2025-08-12T00:20:38-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-012220 2025-08-12T00:36:42-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-012224 2025-08-12T00:36:25-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-012223 2025-08-12T00:37:02-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-012446 2025-08-12T00:37:14-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-013090 2025-08-12T00:37:31-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-013092 2025-08-12T00:37:23-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-013094 2025-08-12T00:37:19-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-013096 2025-08-12T00:37:27-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-034316 2025-08-12T00:37:37-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-013552 2025-08-12T00:37:41-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-014538 2025-08-12T00:37:53-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-014540 2025-08-12T00:38:04-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-014544 2025-08-12T00:37:59-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-014542 2025-08-12T00:37:47-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-23-037446 2025-08-12T00:38:10-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-23-038418 2025-08-12T00:38:15-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-015351 2025-08-12T00:38:20-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-016099 2025-08-12T00:38:24-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4a/0001214659-23-016097 2025-08-12T00:38:39-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-016104 2025-08-12T00:38:29-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-016101 2025-08-12T00:38:44-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-016106 2025-08-12T00:38:34-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/s-3/0001628280-23-041614 2025-08-12T00:38:50-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/del-am/0001628280-23-041679 2025-08-12T00:38:55-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/effect/9999999995-23-003747 2025-08-12T00:39:28-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-017028 2025-08-12T00:39:41-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-017030 2025-08-12T00:39:31-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-017033 2025-08-12T00:39:45-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-23-017035 2025-08-12T00:39:38-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/corresp/0001628280-23-042428 2025-08-12T00:39:05-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/upload/0000000000-23-013833 2025-08-12T00:38:59-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/sc-13g/0001628280-24-004125 2025-08-12T00:39:49-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-24-009006 2025-08-12T00:39:57-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-k/0001628280-24-010725 2025-08-12T00:40:01-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/def-14a/0001628280-24-010960 2025-08-12T00:40:10-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/defa14a/0001628280-24-010965 2025-08-12T00:40:07-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/424b5/0001628280-24-012256 2025-08-12T00:40:25-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-24-012261 2025-08-12T00:40:19-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/ars/0001628280-24-012732 2025-08-12T00:40:30-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-005208 2025-08-12T00:15:04-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-005213 2025-08-12T00:40:47-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-005211 2025-08-12T00:15:18-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-005215 2025-08-12T00:40:50-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-005217 2025-08-12T00:15:22-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-005219 2025-08-12T00:14:57-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-005224 2025-08-12T00:40:35-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-005221 2025-08-12T00:15:00-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-005222 2025-08-12T00:40:40-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-005226 2025-08-12T00:15:08-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-24-019053 2025-08-12T00:15:26-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-24-021185 2025-08-12T00:15:30-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-24-022658 2025-08-12T00:15:34-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-011867 2025-08-12T00:15:50-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-011873 2025-08-12T00:15:44-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-011871 2025-08-12T00:15:38-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-011869 2025-08-12T00:15:45-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-013685 2025-08-12T00:15:53-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-013687 2025-08-12T00:16:01-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-013691 2025-08-12T00:15:57-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-013689 2025-08-12T00:16:04-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-24-035262 2025-08-12T00:16:09-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-24-036529 2025-08-12T00:16:14-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-016051 2025-08-12T00:16:21-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-016020 2025-08-12T00:16:17-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-016036 2025-08-12T00:16:25-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-016075 2025-08-12T00:16:32-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001214659-24-016035 2025-08-12T00:16:28-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-24-042110 2025-08-12T00:16:39-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-24-042124 2025-08-12T00:16:46-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-24-042120 2025-08-12T00:16:42-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-24-042115 2025-08-12T00:16:35-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-24-045054 2025-08-12T00:16:50-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-24-045329 2025-08-12T00:16:54-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-24-045328 2025-08-12T00:17:02-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-24-045334 2025-08-12T00:16:59-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-24-045331 2025-08-12T00:17:06-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-24-045807 2025-08-12T00:17:10-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-24-046399 2025-08-12T00:17:14-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-24-046730 2025-08-12T00:17:19-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-24-046827 2025-08-12T00:17:23-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-24-050104 2025-08-12T00:17:35-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-24-050111 2025-08-12T00:17:27-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-24-050107 2025-08-12T00:17:39-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-24-050113 2025-08-12T00:17:31-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-24-050499 2025-08-12T00:17:43-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-24-052603 2025-08-12T00:17:56-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-24-052606 2025-08-12T00:17:47-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-24-052608 2025-08-12T00:18:00-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-24-052610 2025-08-12T00:17:51-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4a/0001628280-25-003181 2025-08-12T00:18:17-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4a/0001628280-25-003184 2025-08-12T00:18:09-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4a/0001628280-25-003183 2025-08-12T01:18:10-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4a/0001628280-25-003185 2025-08-12T00:18:13-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4a/0001628280-25-003186 2025-08-12T00:18:04-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-25-003753 2025-08-12T00:10:19-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/0001104659-25-011461 2025-08-12T00:10:23-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/0001628280-25-005480 2025-08-12T00:10:32-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-25-005744 2025-08-12T00:10:36-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/424b5/0001628280-25-005760 2025-08-12T00:10:32-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-25-006430 2025-08-12T00:10:40-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-25-009967 2025-08-12T00:10:44-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-k/0001628280-25-011366 2025-08-12T00:10:48-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/defa14a/0001628280-25-011736 2025-08-12T00:10:56-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/def-14a/0001628280-25-011735 2025-08-12T00:10:52-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-013513 2025-08-12T00:11:21-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-013522 2025-08-12T00:11:05-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-013527 2025-08-12T00:11:31-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-013531 2025-08-12T00:11:12-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-013538 2025-08-12T00:13:16-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-013534 2025-08-12T00:11:15-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-013544 2025-08-12T00:10:59-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-013541 2025-08-12T00:11:18-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-013546 2025-08-12T00:11:02-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-013548 2025-08-12T00:11:26-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/ars/0001628280-25-013572 2025-08-12T00:11:09-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-25-013875 2025-08-12T00:12:13-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-016743 2025-08-12T00:12:23-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-016741 2025-08-12T00:12:16-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-016742 2025-08-12T00:12:26-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-016745 2025-08-12T00:12:19-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/schedule-13ga/0001104659-25-038616 2025-08-12T00:12:30-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-25-020222 2025-08-12T00:12:34-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-25-022753 2025-08-12T00:12:37-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-024346 2025-08-12T00:08:22-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-25-024342 2025-08-12T00:08:15-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-024353 2025-08-12T00:08:03-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-024355 2025-08-12T00:08:19-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-024349 2025-08-12T00:08:10-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/schedule-13g/0000950170-25-072872 2025-08-12T00:08:26-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-029849 2025-08-12T00:08:34-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-029852 2025-08-12T00:08:39-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-029854 2025-08-12T00:08:30-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-029856 2025-08-12T00:08:41-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-034814 2025-08-12T00:08:49-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-034816 2025-08-12T00:08:56-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-034818 2025-08-12T00:08:53-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-034820 2025-08-12T00:08:46-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001628280-25-037923 2025-08-12T00:09:00-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001628280-25-039326 2025-08-08T17:05:06-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-039397 2025-08-11T08:41:01-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-039400 2025-08-11T08:53:31-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-039404 2025-08-11T09:03:16-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-039411 2025-08-11T09:16:58-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-041983 2025-09-12T08:37:52-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-041987 2025-09-12T08:38:16-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-041985 2025-09-12T08:38:16-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-25-041989 2025-09-12T08:39:08-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-25-000006 2025-10-03T16:03:51-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-25-000007 2025-10-03T16:03:59-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-25-000008 2025-10-03T16:04:13-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001684087-25-000004 2025-10-03T16:06:06-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001087294-25-000012 2025-10-21T09:26:56-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/schedule-13ga/0001104659-25-104396 2025-10-30T16:20:45-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001075050-25-000006 2025-11-03T07:59:04-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001695580-25-000004 2025-11-03T07:59:05-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001490829-25-000005 2025-11-03T08:01:23-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001684087-25-000008 2025-11-03T08:04:04-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001087294-25-000017 2025-11-04T17:14:18-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-q/0001087294-25-000020 2025-11-07T17:10:12-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001087294-25-000023 2025-11-24T10:25:08-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-25-000025 2025-12-01T17:04:24-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-25-000027 2025-12-01T17:06:27-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001490829-25-000007 2025-12-01T17:08:49-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-25-000029 2025-12-01T17:13:08-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/upload/0000000000-25-009049 2025-12-22T01:13:31-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/upload/0000000000-25-008156 2025-12-22T01:13:41-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/corresp/0001628280-25-040570 2025-12-22T01:13:54-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-26-000002 2026-01-06T17:06:30-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-26-000008 2026-01-06T17:06:38-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-26-000006 2026-01-06T17:06:38-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-26-000004 2026-01-06T17:10:12-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001087294-26-000011 2026-02-04T17:21:41-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/schedule-13g/0001075050-26-000006 2026-02-09T17:13:33-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/8-k/0001087294-26-000015 2026-03-03T17:11:34-05:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/10-k/0001087294-26-000020 2026-03-09T06:08:50-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/defa14a/0001087294-26-000027 2026-03-09T17:04:52-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/def-14a/0001087294-26-000025 2026-03-09T17:04:53-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/ars/0001087294-26-000029 2026-03-12T17:02:57-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001628280-26-019514 2026-03-18T17:40:41-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-26-000034 2026-03-20T17:22:30-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-26-000032 2026-03-20T17:22:30-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-26-000033 2026-03-20T17:22:43-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001572342-26-000002 2026-03-20T17:22:43-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-26-000035 2026-03-20T17:23:46-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-26-000036 2026-03-20T17:24:30-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-26-000037 2026-03-20T17:24:30-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-26-000039 2026-03-20T17:25:43-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001632384-26-000002 2026-03-20T17:26:54-04:00 0.4 https://investor.cumberlandpharma.com/sec-filings/sec-filing/4/0001087294-26-000040 2026-03-20T17:27:49-04:00 0.4 https://investor.cumberlandpharma.com/corporate-update 2026-03-10T13:11:55-04:00 0.4 https://investor.cumberlandpharma.com/board-directors/aj-kazimi 2024-08-16T14:46:16-04:00 0.5 https://investor.cumberlandpharma.com/board-directors/gordon-bernard 2024-08-16T14:46:14-04:00 0.5 https://investor.cumberlandpharma.com/board-directors/james-jones 2024-08-16T14:46:11-04:00 0.5 https://investor.cumberlandpharma.com/board-directors/caroline-young 2024-08-16T14:46:09-04:00 0.5 https://investor.cumberlandpharma.com/board-directors/kenneth-krogulski 2024-08-16T14:46:06-04:00 0.5 https://investor.cumberlandpharma.com/board-directors/joseph-c-galante 2024-08-16T14:46:04-04:00 0.5 https://investor.cumberlandpharma.com/board-directors/martin 2024-08-16T14:46:02-04:00 0.5